COMPANY
Oruka Therapeutics
Since the raise (Apr 28, 2026): 18 of 18 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Manager, Clinical Data Management | Remote | Oct 6, 2026 | Oct 8, 2026 |
| Senior Manager, Clinical Supply Chain – Biologics | Waltham, Massachusetts, United States | Oct 2, 2026 | Oct 8, 2026 |
| Associate Director, Biostatistics | Menlo Park, California, United States; Remote; Waltham, Massachusetts, United States | Oct 2, 2026 | Oct 8, 2026 |
| Director of Biostatistics | Menlo Park, California, United States; Remote; Waltham, Massachusetts, United States | Oct 2, 2026 | Oct 8, 2026 |
| Senior Engineer/Manager, Device Development — Combination Products | Waltham, Massachusetts, United States | Oct 1, 2026 | Oct 8, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 2 trial (NCT07783542, actual start Aug 21, 2026); since then posted 8 clinical-operations roles. ClinicalTrials.gov NCT07783542 (Aug 21, 2026)
Evidence (1 event)
- Aug 21, 2026 · ClinicalTrials.gov NCT07783542
leadSponsor.name='Oruka Therapeutics, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-24; briefTitle='ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa'
- Aug 21, 2026 · ClinicalTrials.gov NCT07783542
Timeline
- Board tracked Radar started tracking this company’s job board (18 open jobs at last check). source ↗
- Trial start Phase 2: ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa source ↗
- Raise Follow-on offering: $700.4M (total, as published), announced Apr 28, 2026. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 2: Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis source ↗
- Trial start Phase 2: An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis source ↗
- Trial start Phase 2: Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis source ↗
- Raise Private placement: $180M (total, as published), announced Sep 17, 2025. Source: SEC filing. source ↗
- Trial start Phase 2: ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis source ↗
- Trial start I: ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose source ↗
- Trial start Phase 1: ORKA-001 in Healthy Volunteers source ↗
Upcoming milestones
- 2027-01 (ESTIMATED) · I · ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose · NCT06944379
- 2027-06 (ESTIMATED) · Phase 2 · Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis · NCT07290569
- 2027-10 (ESTIMATED) · Phase 2 · Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis · NCT07474792
- 2028-10 (ESTIMATED) · Phase 2 · ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa · NCT07783542
- 2030-05 (ESTIMATED) · Phase 2 · An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis · NCT07449702
Open jobs 18
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Manager, Clinical Data Management | Remote | Oct 6, 2026 | Oct 8, 2026 | Senior |
| Senior Manager, Clinical Supply Chain – Biologics | Waltham, Massachusetts, United States | Oct 2, 2026 | Oct 8, 2026 | Senior |
| Associate Director, Biostatistics | Menlo Park, California, United States; Remote; Waltham, Massachusetts, United States | Oct 2, 2026 | Oct 8, 2026 | Senior |
| Director of Biostatistics | Menlo Park, California, United States; Remote; Waltham, Massachusetts, United States | Oct 2, 2026 | Oct 8, 2026 | Senior |
| Senior Engineer/Manager, Device Development — Combination Products | Waltham, Massachusetts, United States | Oct 1, 2026 | Oct 8, 2026 | Senior |
| Medical Director, Clinical Development | Remote; Waltham, Massachusetts, United States | Sep 25, 2026 | Oct 8, 2026 | Senior |
| Senior Medical Director, Pharmacovigilance and Safety | Remote; Waltham, Massachusetts, United States | Sep 25, 2026 | Oct 8, 2026 | Senior |
| Pharmacovigilance Scientist | Remote; Waltham, Massachusetts, United States | Sep 25, 2026 | Oct 8, 2026 | Mid |
| Clinical Scientist, Clinical Development | Remote | Sep 25, 2026 | Oct 12, 2026 | Mid |
| Manager/Senior Manager of Statistical Programming | Remote; Waltham, Massachusetts, United States | Sep 21, 2026 | Oct 8, 2026 | Mid |
| Sr. Associate/Manager Project Management & Operations | Waltham, Massachusetts, United States | Aug 20, 2026 | Oct 8, 2026 | Mid |
| Senior Manager/Associate Director Clinical Monitoring Strategy & Optimization | Menlo Park, California, United States; Remote; Waltham, Massachusetts, United States | Jul 27, 2026 | Oct 8, 2026 | Senior |
| Associate/Sr. Associate - CMC Project Management & Operations | Waltham, Massachusetts, United States | Jul 6, 2026 | Oct 8, 2026 | Mid |
| Biosample Operations Associate | Menlo Park, California, United States; Remote; Waltham, Massachusetts, United States | Jun 11, 2026 | Oct 8, 2026 | Mid |
| Director, Clinical Operations | Waltham, Massachusetts, United States | May 29, 2026 | Oct 8, 2026 | Senior |
| Medical Science Liaison-Southeast | Remote | May 6, 2026 | Oct 8, 2026 | Mid |
| Medical Science Liaison-South Central | Remote | May 6, 2026 | Oct 8, 2026 | Mid |
| Director / Senior Director, Regulatory CMC (Biologics) | Waltham, Massachusetts, United States | Apr 10, 2026 | Oct 8, 2026 | Senior |
Funding
Clinical trials (lead sponsor) 7
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07783542 | ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa | Phase 2 | Recruiting | Aug 21, 2026 | 2028-10 (estimated) |
| NCT07449702 | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | Phase 2 | Recruiting | Feb 23, 2026 | 2030-05 (estimated) |
| NCT07290569 | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Phase 2 | Active, not recruiting | Dec 3, 2025 | 2027-06 (estimated) |
| NCT07474792 | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Phase 2 | Recruiting | Mar 19, 2026 | 2027-10 (estimated) |
| NCT07090330 | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | Phase 2 | Active, not recruiting | Jul 18, 2025 | Mar 25, 2026 (actual) |
| NCT06698939 | ORKA-001 in Healthy Volunteers | Phase 1 | Completed | Dec 19, 2024 | Mar 13, 2026 (actual) |
| NCT06944379 | ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose | I | Active, not recruiting | May 19, 2025 | 2027-01 (estimated) |
Connect
See your connections at Oruka Therapeutics on LinkedIn (search by name, results not checked)